Everything drug pricing and policy, every day
And it’s a quiet day -- but probably a noisy week -- when it comes to drug-pricing news
And the White House wants Congress to codify its MFN policies. Republicans are (appropriately) skeptical.
And there’s reporting that the launch of TrumpRx is imminent, though questions persist
And HHS is working to identify and limit legal risks around TrumpRx and other pharm-to-table programs
And hospitals strike back as Lilly moves to require more data from in-house pharmacies at 340B providers
And the PBM reform timeline may slip as the Minneapolis killing scrambles legislative efforts on spending bills
But the Cigna CEO makes a notable disclosure about the cost of moving away from drug rebates
And a sampling of the best LinkedIn health policy content from the past week or so
And HEOR leaders assess how pharma strategies will change in light of IRA, MFN pressures
